natgillin/translations-raw huggingface dataset:
In some embodiments, the surfactant can be polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl 40 stearate, polyoxyl 150 stearate, polyoxyl 150 distearate, d-a-tocopheryl polyethylene glycol 1000 succinate, poloxamer 124, poloxamer 188, poloxamer 407, sorbitan monolauryl ester, sorbitan monopalmityl ester, sorbitan monostearyl ester, or a mixture of any two or more thereof. 
Sastav prema patentnom zahtjevu 3, naznačen time, da površinski aktivna tvar jest polioksil 35 ricinusovo ulje, polioksil 40 hidrirano ricinusovo ulje, polioksil 60 hidrirano ricinusovo ulje, polisorbat 20, polisorbat 40, polisorbat 60, polisorbal 80, polioksil 40 stearal, polioksil 150 stearal, polioksil 150 distearat, d-a-tokoferil polietilen glikol 1000 sukcinat, poloksamer 124, poloksamer 188, poloksamer 407, sorbitan monolauril ester, sorbitan monopalmitil ester, sorbitan monostearil ester, ili smjesa od bilo kojeg od dvoje ili od više njih.
Carbonaceous fuel elements are preferably from about 5 to 15 mm, more preferably, from about 8 to 12 mm in length. 
Ugljični gorivi elementi su poželjno od oko 5 do 15 mm, poželjnije dužine od oko 8 do 12 mm.
The grit as claimed in claim 1, in which the ZrO2 content is greater than 40.0%. 
Sitna zrnca prema prethodnim zahtjevima, naznačena time da je sadržaj ZrO, veći od 40.0%.
A nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide according to claim 1 . 
Molekulu nukleinske kiseline koji sadrži sekvencu nukleinske kiseline koja kodira polipeptid sukladno bilo kojem od patentnih zahtjeva 1-3.
The residue was treated by sodium chloride solution and n-hexane extracted. 
Ostatak se obradi otopinom natrij klorida i ekstrahira nheksanom.
The video decoding apparatus of claim 1, wherein the maximum split information for the transformation unit with the intra mode is obtained as parameters with respect to one data level from among data levels comprising a picture sequence, a picture, a slice, and a data unit for encoding a video. 
Uređaj za dekodiranje video zapisa prema zahtjevu 1, naznačen time što se informacija o maksimalnom dijeljenju za transformacijsku jedinicu s intra načinom dobije kao parametri u odnosu na jednu razinu podataka između razina podataka koje sadrže niz slika, sliku, odsječak, 1 jedinicu podataka za kodiranje videa.
• separated from the client computer and comprises a user interface through which the secret can be presented to the user. 
* > odvojenaje od računala klijenta i sadrži korisničko sučelje preko kojeg se tajna može prikazati korisniku.
The product precipitated and was removed by filtration, washed with water and dried. 
Produkt se ostavi istaložiti, te se ukloni filtracijom, ispere s vodom i osuši.
expression of one or more functional neural markers (e.g. synapsin) after differentiation into a neuronal-like cell; 
- < ekspresiju jednog ili više funkcionalnih neuronskih markera;
A pharmaceutical composition according to claim 16, wherein the unit dose provides a dose of oxycodone sufficient to provide analgesia to a human patient. 
Farmaceutski oblik prema zahtjevu 14, gdje pojedinačna doza daje dozu oksikodona koja je dovoljna za analgetski učinak u ljudskog bolesnika.
The compound or pharmaceutically acceptable salt for use according to claim 26, wherein the further medicament is natalizumab, dimethyl fumarate, an interferon, or glatiramer acetate, optionally wherein the interferon is a pegylated interferon, a non-pegylated interferon, interferon B-1a or pegylated interferon B -1 a. 
Spoj ili farmaceutski prikladna sol za uporabu prema zahtjevu 26, gdje je dodatni lijek natalizumab, dimetil fumarat, interferon, ili glatiramer acetat, po izboru gdje je interferon pegilirani interferon, ne-pegilirani interferon, interferon B-1a ili pegilirani interferon B-1a.
The polymer hydrogel of claim 4 wherein the weight ratio of carboxymethylcellulose to hydroxyethylcellulose in the aqueous solution is from 2:1 to 5:1. 
Polimerni hidrogel u skladu s patentnim zahtjevom 4, naznačen time da je težinski omjer karboksimetilceluloze naspram hidroksietilceluloze u vodenoj otopini od 2:1 do 5:1.
The method of claim 29 wherein the disease or disorder is a tumor-related disease. The method of claim 30 wherein the tumor-related disease is selected from the group consisting of gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. 
Protutijelo, konjugat ili farmaceutski sastav za uporabu u skladu s patentnim zahtjevom 10 pri čemu je bolest ili poremećaj bolest povezana s tumorom, pri čemu je bolest povezana s tumorom poželjno odabrana iz grupe koja se sastoji od karcinoma dojke, karcinoma želuca, karcinoma jednjaka, karcinoma gušterače, karcinoma pluća, karcinoma jajnika, karcinoma debelog crijeva, kolorektalnog karcinoma, karcinoma jetre, karcinoma glave i vrata, karcinoma žučnog mjehura i njihovih metastaza.
In the latter case the sealing member can be mounted releasably to the base body 4 or fixed thereto e.g. by welding or by means of an adhesive. 
U ovom posljednjem slučaju element za nepropusno zatvaranje može biti montiran na osnovno tijelo 4, na takav način da se može skidati, ili može biti pričvršćen na njega, na primjer, zavarivanjem ili pomoću nekog ljepila.
The resulting suspension is sonicated and allowed to stir at room temperature overnight. 
Dobivenu suspenziju se izloži ultrazvuku i pusti se miješati preko noći sobnoj temperaturi.
The process according to any one of claims 1 to 10, wherein the at least one mono-substituted succinic anhydride of step b) is at least one alkenyl mono-substituted succinic anhydride, preferably at least one alkenyl mono-substituted succinic anhydride selected from the group comprising ethenylsuccinic anhydride, propenylsuccinic anhydride, butenylsuccinic anhydride, triisobutenyl succinic anhydride, pentenylsuccinic anhydride, hexenylsuccinic anhydride, heptenylsuccinic anhydride, octenylsuccinic anhydride, nonenylsuccinic anhydride, decenyl succinic anhydride, dodecenyl succinic anhydride, hexadecenyl succinic anhydride, octadecenyl succinic anhydride, and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time da je barem jedan mono-supstituirani sukcinski anhidrid iz koraka b) barem jedan alkenil mono-supstituirani sukcinski anhidrid, poželjno barem jedan alkenil mono-supstituirani sukcinski anhidrid odabran iz skupine koju čine etenilsukcinski anhidrid, propenilsukcinski anhidrid, butenilsukcinski anhidrid, triizobutenil sukcinski anhidrid, pentenilsukcinski anhidrid, heksenilsukcinski anhidrid, heptemilsukcinski anhidrid, oktenilsukcinski anhidrid, nonenilsukcinski anhidrid, decenil sukcinski anhidrid, dodecenil sukcinski anhidrid, heksadecenil sukcinski anhidrid, oktadecenil sukcinski anhidrid, i njihove smjese.
A compound of the formula: 
Spoj naznačen time da ima formulu
The amount of solid carrier may vary but will usually be from about 25 mg to about 1 g. 
Količina krutog nosača može varirati I obično je u količini od 25 mg do oko 1 g.
The method of claim 1, wherein the pH of the solution in step c is adjusted to from 6.0 to 7.5, or from 7.0 to 7.5 by a weak acid, and wherein the weak acid is an inorganic acid, an organic acid or a combination thereof, or the weak acid is dilute acetic acid, dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid or a combination thereof. 
Postupak prema bilo kojem od zahtjeva 1-7, naznačen time da se pH otopine u koraku c) podešava na od 6.0 do 7.5, ili od 7.0 do 7.5 sa slabom kiselinom, te pri čemu slaba kiselina je anorganska kiselina, organska kiselina ili njihova kombinacija, ili slaba kiselina je razrijeđena octena kiselina, razrijeđena solna kiselina, razrijeđena sumporna kiselina, razrijeđena fosforna kiselina, razrijeđena dušična kiselina ili njihova kombinacija.
the proximal end of the first fragment is located within a first repeat portion; 
prvi fragment ima prvi proksimalni kraj;
The solvent was evaporated off, and aqueous sodium hydroxide (2M, 200 mL), and ethyl acetate (400 mL) were added. 
Otapalo je upareno, a dodani su vodena otopina natrijevog hidroksida (2M, 200 mL) i etil acetat (400 mL).
Process according to Embodiment 1, where both the stripper, as well as the second reaction section are located at ground level. 
Postupak sukladno zahtjevu 1, pri čemu su ekstrahator, kao i drugi odjeljak reaktora postavljeni na razini tla.
treatment of the ester of the formula VII with a base B providing the 1,3-diketone of the formula VIII; 
obradi estera formule VII bazom B, čime se dobije 1,3-diketon formule VIII;
The packaging and the device for manual rolling of cigarettes as claimed in claim 4, further comprising variously shaped clamps may be arranged instead of the lugs (6 g ′) and the openings (6 a ′). 
Pakiranje i uređaj za ručno motanje cigareta, prema zahtjevu 5, naznačen/o time, da umjesto uha (6g') i otvora (6a), mogu se rasporediti spone različitih oblika.
A packaging according to claim 1, wherein the hinging part allows the sides to be rotated relative to each other within an angle of 200° or more. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što zglobni dio omogućava da se strane zakreću jedna u odnosu na drugu unutar kuta od 200? ili više, odnosno kuta od 240", tada kada se pakiranje otvori.
The invention applies to the oil-producing industry and is intended for the intensification of the processes of increasing the yield of oil wells used for the production of high-viscosity oils. 
Područje prijave Izum se primjenjuje u naftnoj industriji i namijenjen je za pojačanje postupaka povećanja prinosa iz naftnih izvora koji se koriste za proizvodnju nafte visoke viskoznosti.
The crystalline structure as defined in Claim 1 having the formula 1b 
Kristalna struktura kako je definirano u zahtjevu 1 naznačena time da ima formulu Ib [image]
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbomen-5-il)amid, a kao komponentu (B) klorotalonil.
The chemical structure of tetrabenazine is as shown in Figure 1 below. 
Kemijska struktura tetrabenazina je prikazana na Slici 1 dolje.
a threaded stem (13), which is fixed at right angles to the base (11) in at least one easily breakable point (14), 
- < navojno deblo (13) koje je učvršćeno pod pravim kutovima prema osnovi (11) u najmanje jednoj lako prijelomnoj točki (14), 1
In an embodiment the alignment frame (62) and the load bearing frame (61) are joined by joining part of the overlapping inner rims of the concave openings of each frame (61, 62). 
Preša (1) prema prethodnom patentnom zahtjevu gdje podešavajući okvir (62) i noseći okvir (61) su spojeni spajajućim dijelom preklapajućih unutrašnjih rubova konkavnih otvora svakog okvira (61, 62).
A compound according to claim 7, wherein R2 is COR4. A compound according to claim 10 wherein R4 is C1-10 unbranched or branched alkyl. 
Spoj prema patentnom zahtjevu 7, naznačen time što, R* je COR", pri čemu, R* je Cro nerazgranati ili granati alkil.
Method for producing a freeze-dried molded article according to any one of the embodiments 1 to 18, comprising the following steps: 
Postupak proizvodnje liofiliziranog oblikovanog proizvoda sukladno zahtjevu 1 do 6, obuhvaća sljedeće korake:
As coating liquid a solution of 60.0 g of ethylcellulose (viscosity: 10 centipoise) and 6.0 g of copovidone (vinylpyrrolidone acetate (60/40) copolymer) in 550.0 g of 96% by volume ethanol were used, in which 18.0 g of talc had been suspended as antiadhesive. 
Kao tekućina za prevlačenje korištena je otopina 60,0 g etilceluloze (viskoznost: 10 centipoise) i 6,0 g kopovidona (vinilpirolidon acetat (60/40) kopolimer) u 550,0 g 96% (volumno) etanola, u čemu je suspendirano 18,0 g talka kao antiadheziva.
Process according to claim 9, characterised in that step b) is carried out at a temperature of approximately 900°C, the reactions for thermal cracking of tars being conducted. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time što se korak b) provodi na temperaturi od otprilike 900°C, gdje se provode reakcije toplinskog krekiranja katrana.
the two human Vk gene segments and the five human Jk gene segments are operably linked to a mouse or rat immunoglobulin light chain constant region sequence which is (i) a rat Ck region or (ii) a mouse Ck region; and/or 
dva humana segmenta gena Vk i pet humanih segmenata gena Jk su operativno povezani sa sekvencom konstantne regije lakog lanca mišjeg ili štakorskog imunoglobulina koja je (i) štakorska regija Ck ili (ii) mišja regija Ck; i/ili
The compound or the pharmaceutical composition for use according to claim 9, wherein said parkinsonism and movement disorders are selected from: Parkinson's disease; multiple system atrophy; progressive supranuclear palsy; corticobasal degeneration; hepatolenticular degeneration; chorea, including Huntington's disease and hemiballismus; athetosis; dystonias, including spasmodic torticollis, occupational movement disorder, and Gilles de la Tourette syndrome; tardive or drug induced dyskinesias, including levodopa-induced dyskinesia; tremor; or myoclonus. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 6, naznačen time što je navedeno stanje odabrano od parkinsonizma i poremećaja kretanja, 1 pri čemu su navedeni parkinsonizam i poremećaji kretanja dalje odabrani od: Parkinsonove bolesti, multiple atrofije sustava, progresivne supranuklearne paralize, kortikobazalne degeneracije; hepatolentikularne degeneracije; koreje, uključujući Huntingtonovu bolest i hemibalizam; atetoze; distonija, uključujući spastični tortikolis, profesionalni poremećaj kretanja, i Gilles de la Tourette sindrom; zakašnjele 1l1 diskinezije izazvane lijekom, uključujući diskineziju izazvanu levodopom; treskavice; ili mioklonusa.
Intermediate of formula (6') is dissolved in THF and the solution is added with 10 eq of 1M LiOH in water. 
Međuprodukt formule (6') je otopljen u THF i otopina je dodana vodi s 10 ekviv. IM LiOH.
The mixture is left with mechanical stirring for 12 hours under reflux. 
Smjesa je ostavljena uz mehaničko miješanje 12 sati pod refluksom.
The process of claim 1 wherein the anion is selected from the group consisting of halogen, mesylate, tosylate, brosylate, nosylate, and triflate. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se anion bira iz skupine koju čine halogen, mesilat, tosilat, brosilat, nosilat i triflat.
The isoquinoline derivative of claim 1, wherein X is O, S or NH; 
Izokinolinski derivat u skladu s patentnim zahtjevom 1, gdje Xje 0, Sili NH;
The method according to claim 1, wherein said ionizing radiations are selected from the group consisting of X-Rays, Y-Rays, electron beams and radioisotope emissions. 
Uporaba prema bilo kojem od zahtjeva 1 1 4, ili nanočestice HfO, ili agregati nanočestica HfO, za uporabu prema bilo kojem od zahtjeva 2, 3 i 4, gdje su spomenuta ionizirajuća zračenja odabrana iz skupine koju čine X-zrake, y-zrake, elektronski snopovi i zračenja radioizotopa.
In one embodiment of the invention, said cancer is selected from breast cancer, Non-Hodgkins lymphoma, pancreatic cancer, hepatocellular cancer, gastric cancer, prostate cancer and lung cancer. 
Spoj prema zahtjevu 10 naznačen time da je za uporabu kod liječenja raka gdje je rak odabran od raka dojke, ne-Hodgkinovog limfoma, raka gušterače, hepatocelularnog karcinoma, raka želuca, raka prostate i raka pluća.
is, in case of c being a single bond, either hydrogen or C1 to C6 alkyl, or in case of c being a double bond, CHR5, wherein R5 is the same as defined before; and 
R: je, u slučaju ako je c jednostruka veza, bilo vodik ili C, do Cg alkil, ili u slučaju ako je c dvostruka veza, CHRe, gdje je Rs isti kao što je definirano ranije;
The coating material as recited in claim 1, wherein the etherified melamine-formaldehyde resin is selected from the group consisting of a methanol-etherified melamine-formaldehyde resin, an ethanol-etherified melamine-formaldehyde resin, a propanol-etherified melamine-formaldehyde resin, an isobutanol-etherified melamine-formaldehyde resin, and an n-butanol-etherified melamine-formaldehyde resin. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da su eterificirane smole melamin-formaldehida odabrane iz skupine koju čine smole metanol-melamin-formaldehida, etanol-eterificirane smole melamin-formaldehida, propanol-eterificirane smole melamin-formaldehida, izo-hutanol-eterificirane smole melamin-formaldehida i n-butanol-eterificirane smole melamin-formaldehida.
The process according to any of claims 1 to 22, characterised in that the C8 to C24 aliphatic monocarboxylic acid of the Group II or Group III salt(s) of a C8 to C24 aliphatic monocarboxylic acid employed in step (a) and the C8 to C24 aliphatic carboxylic acid(s) employed in step (b) are not equivalent. 
Postupak prema bilo kojem od zahtjeva 1 do 12, naznačen time da C8 do C24 alifatska monokarboksilna kiselina Skupine II- ili Skupine III-soli C8 do C24 alifatske monokarboksilne kiseline koja se koristi u koraku (a) i C8 do C24 alifatska karboksilna kiselina odnosno alifatske karboksilne kiseline koje se koriste u koraku (b) nisu ekvivalentne.
In one embodiment, the cell is selected from an embryonic stem (ES) cell, a pluripotent cell, an induced pluripotent cell, and a totipotent cell. 
(b) ciljana stanica je tumorska stanica, a imunoadhezin ili antitijelo se specifično vezuje za epitop tumorske stanice.
The compound of claim 1 wherein R1 is (C1-C6)alkyl, (C3-C7)cycloalkyl, or tetrahydrofuranyl; and R2 is hydrogen or methyl; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R' (C,-Cs)alkil, (C3-Cy)cikloalkil ili tetrahidrofuranil; a R" je vodik ili metil; ili njegova farmaceutski prihvatljiva sol.
The method of statement 1 wherein the drive signal having the first frequency and the drive signal having the second frequency overlap. 
Sustav u skladu sa zahtjevom 1, naznačen time, da su upravljačka sredstva nadalje podešena da prenose upravljački signal tako da se prva frekvencija i druga frekvencija preklapaju.
independently represents a halogen atom or an alkyl group having from 1 to 2 carbon atoms; m is 0, 1 or 2; and 
R* neovisno predstavlja atom halogena ili alkilnu skupinu s 1 do 2 atoma ugljika; mje0,lili2;i
5 and 6 are respective longitudinal and transverse sectional illustrations of the cylinder lock of FIG. 4 with the key of FIG. 1 inserted in a keyway thereof, showing the orientation of the key combination element when the lock elements of the cylinder lock are aligned along the shear line, in accordance with an embodiment of the present invention. 
Slike 516 su prikazi uzdužnog i poprečnog presjeka cilindrične brave sa Slike 4, s umetnutim ključem sa Slike 1 u put ključa te brave, a može se vidjeti položaj elementa kombinacije ključa kada su elementi zaključavanja cilindrične brave poredani duž linije razgraničenja, u skladu s ostvarenjem predstavljenog izuma.
A method of preparation of Chimeric Antigen Receptor (CAR) which comprises the steps of: providing a polynucleotide encoding an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 12, in particular a scFv fragment, 
Postupak za pripremu himernog receptora antigena (CAR) koji sadrži korake: a. = osiguravanja polinukleotida koji kodira antitijelo ili njegov antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naročito scFv fragment, b.
a conjugate comprising (i) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof having at least 10% of the activity of human IL-15 on the proliferation induction of kit225 cell line, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Ra or derivatives thereof having at least 10% of the binding activity of the sushi domain of human IL-15Ra to human IL-15, a polynucleotide coding therefore, or a vector comprising such a polynucleotide; and 
konjugat koji sadrži polipeptid koji sadrži aminokiselinsku sekvencu interleukina 15 ili njegovih derivata koji imaju najmanje 10% aktivnosti ljudskog IL-15 na indukciju proliferacije stanice kit225, i polipeptid koji sadrži aminokiselinski slijed suši domene IL-15Ra ili njegovih derivata koji imaju najmanje 10% aktivnosti vezanja suši domene ljudskog IL-15Ra na humani IL-15, polinukleotid koji kodira, ili vektor koji sadrži takav polinukleotid; i
A dual specificity antibody fusion protein according to claim 1, comprising a Fab or Fab' fragment, with a first specificity for an antigen of interest, and further comprises two single domain antibodies (dAb) with specificity for a second antigen of interest, which binds human serum albumin and wherein the two single domain antibodies are linked by a disulphide bond and one of said single domain antibodies is a heavy chain VH single domain antibody which comprises the sequence given in SEQ ID NO: 56 for CDRH1, the sequence given in SEQ ID NO: 57 for CDRH2 and the sequence given in SEQ ID NO: 58 for CDRH3 and the other single domain antibody is a light chain VL single domain antibody which comprises the sequence given in SEQ ID NO: 59 for CDRL1, the sequence given in in SEQ ID NO: 60 for CDRL2, and the sequence given in SEQ ID NO: 61 for CDRL3. 
Dvostruko specifični fuzijski protein protutijela prema zahtjevu 1, naznačen time da sadrži Fab ili Fab' fragment, sa prvom specifičnosti za antigen od interesa, te nadalje sadrži dva protutijela jedne domene (dAb) sa specifičnosti za drugi antigen od interesa, koja vežu ljudski serumski albumin i pri čemu su dva protutijela jedne domene vezana s disulfidnom vezom i jedno od navedenih protutijela jedne domene je protutijelo jedne domene teškog lanca VH koje sadrži sekvencu navedenu u SEQ ID NO: 56 za CDRH1, sekvencu navedenu u SEQ ID NO: 57 za CDRH2 i sekvencu navedenu u SEQ ID NO: 58 za CDRH3 i drugo protutijelo jedne domene je protutijelo jedne domene lakog lanca VL koje sadrži sekvencu navedenu u SEQ ID NO: 59 za CDRL1, sekvencu navedenu u SEQ ID NO: 60 za CDRL2, te sekvencu navedenu u SEQ ID NO: 61 za CDRL3.
A method according to claim 1 wherein the food product is fluid. 
Postupak prema zahtjevu 1 gdje je prehrambeni proizvod tekućina.
The bag as claimed in claim 1, wherein the layer of plastic film is affixed to the at least one underlying paper layer only at a plurality of points and is removable from the at least one paper layer. 
Vreća u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je plastični film pričvršćen na osnovni sloj papira samo na mjestima, te se zato lako skida sa sloja papira.
The system according to claim 14, further comprising means for releasing the energy captured and stored by exothermic hydrolysis. 
Sistem prema zahtjevu 14, koji je dalje naznačen time što sadrži sredstva za oslobađanje sakupljene i uskladištene energije u sljedećem koraku egzotermne hidrolize.
Thus compound of the example 1 has been administered to rats at doses of 30 mg/kg for 7 days and no adverse toxicological effects were observed. 
Tako je spoj iz Primjera 1 7 dana primijenjivan na štakorima u dozama od 30 mg/kg, bez opaženih štetnih toksikoloških učinaka. PATENTNI ZAHTJEVI
a base of the formula RcRdNM, wherein Rc and Rd are independently selected from alkyl, cycloalkyl, heterocyclyl and silyl and M is an alkali metal; and 
baze sa formulom RcRdNM, gdje su Rc i Rd nezavisno izabrani od alkila, cikloalkila, heterociklila ili silila i M je alkalni metal; i
reacting the antioxidant-linker conjugate thus obtained with said pretreated surface obtained in step a). 
reakcije tako dobivenog konjugata antioksidans-spojnica s navedenom predobrađenom površinom dobivenom u koraku a).